[{"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-001", "question": "A 26-year-old G2P1 at 30 weeks' gestation presents with new-onset severe occipital headache, visual scotomata, and right upper quadrant pain. BP is 168/108 mmHg, HR 88, reflexes 3+ with 1-2 beats of clonus. Fetal heart tracing is category I. Labs: platelets 86,000/µL, AST 145 U/L, ALT 162 U/L, creatinine 0.9 mg/dL, urine protein/creatinine ratio 0.5. She received 10 mg IV hydralazine in triage 20 minutes ago; current BP is 162/104 mmHg. She desires future fertility and vaginal delivery if safe. What is the most appropriate NEXT step in management?", "options": ["Administer IV labetalol now and plan for induction of labor at 34 weeks", "Initiate magnesium sulfate and proceed with immediate induction of labor", "Initiate magnesium sulfate and administer betamethasone; plan delivery within 24 hours", "Administer additional IV hydralazine and observe; defer delivery until 34 weeks if blood pressure controlled", "Start oral labetalol and discharge with close outpatient follow-up and twice-weekly NSTs"], "answer": "C", "answer_index": 2, "explanation": "She has preeclampsia with severe features and evolving HELLP (thrombocytopenia, RUQ pain, transaminitis) at 30 weeks. For severe features <34 weeks, optimal care is magnesium, corticosteroids, and expedited delivery within 24 hours at a tertiary center, not expectant management. Immediate induction ignores steroid window and maternal stability; outpatient or prolonged expectant management is unsafe given platelets <100,000 and worsening symptoms.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict: Correct best. Key stem clues: 30 weeks, severe features (severe headache, visual changes, RUQ pain, BP >160/110, clonus), lab evidence of HELLP (thrombocytopenia, transaminitis), and persistent severe-range BP after initial hydralazine. The clinical picture mandates seizure prophylaxis with magnesium sulfate, administration of betamethasone for fetal lung maturation given preterm gestation, and expedited delivery, typically within 24-48 hours for severe preeclampsia with HELLP features. Option C correctly bundles these steps. Alternatives are inferior: A and D delay delivery unjustifiably; B omits steroids; E is unsafe outpatient management. The item is logically valid and medically accurate, aligning with ACOG guidelines for severe preeclampsia with HELLP syndrome. Minimal fix: None required; the item is sound.\",\n  \"logical_false_reason\": \"T\",\n  \"logical_validity\": true,\n  \"medical_accuracy_score\":  \t\n  \"5\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best. Key stem clues: 30 weeks, severe features (severe headache, visual changes, RUQ pain, BP >160/110, clonus), lab evidence of HELLP (thrombocytopenia, transaminitis), and persistent severe-range BP after initial hydralazine. The clinical picture mandates seizure prophylaxis with magnesium sulfate, administration of betamethasone for fetal lung maturation given preterm gestation, and expedited delivery, typically within 24-48 hours for severe preeclampsia with HELLP features. Option C correctly bundles these steps. Alternatives are inferior: A and D delay delivery unjustifiably; B omits steroids; E is unsafe outpatient management. The item is logically valid and medically accurate, aligning with ACOG guidelines for severe preeclampsia with HELLP syndrome. Minimal fix: None required; the item is sound.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-002", "question": "A 58-year-old man with ischemic cardiomyopathy (LVEF 20%), CRT-D in place, and NYHA class III symptoms despite optimal GDMT (sacubitril/valsartan, carvedilol, spironolactone, empagliflozin, loop diuretic) presents with weight gain and dyspnea. BP 104/66 mmHg, HR 72 (biventricular paced), JVP 12 cm, bibasilar crackles, moderate ascites, no peripheral edema. Labs: Na 130 mEq/L, K 4.4, creatinine 1.8 (baseline 1.3), NT-proBNP 12,000 pg/mL. Echo: LVEF 20%, severe functional MR, normal RV size, mildly reduced RV function, PASP 55 mmHg. Right heart cath: RAP 18 mmHg, PCWP 32 mmHg, CI 1.7 L/min/m², SVR 2100 dyn·s/cm⁵. After IV diuresis, he remains hypotensive with CI 1.6. He is INTERMACS profile 4. What is the best definitive next step?", "options": ["Add continuous IV milrinone as palliative inotropic therapy without advanced therapies", "Refer for urgent isolated cardiac transplantation listing status 2 without LVAD bridge", "Evaluate for transcatheter edge-to-edge repair (TEER) of the mitral valve to reduce MR", "Refer for durable LVAD implantation as bridge to transplant or destination therapy", "Implant a percutaneous Impella device as bridge to decision in the ICU"], "answer": "D", "answer_index": 3, "explanation": "He has advanced, stage D HFrEF with persistent low-output symptoms, high filling pressures, and INTERMACS profile 4, making him appropriate for durable LVAD as bridge to transplant or destination. Isolated transplant without LVAD is not ideal given instability; TEER is for less advanced, stable patients. Chronic inotropes or short-term MCS alone are not definitive strategies in a transplant/LVAD candidate.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: V. Verdict: Correct best. Key stem clues: advanced HFrEF (LVEF 20%, NYHA III on GDMT), INTERMACS 4 (recurrent but not refractory shock), persistent low cardiac index (1.6) and hypotension after diuresis, and high filling pressures. This profile defines a candidate for durable mechanical circulatory support. Main logical issue: None; the stem clearly supports a single best answer. Main medical accuracy issue: None; the logic aligns with current guidelines for advanced heart failure management. Minimal fix: None required; the item is well-constructed. Alternative E (Impella) is a short-term bridge, not definitive. C (TEER) is for less severe, stable patients. A (milrinone) is palliative, not definitive. B (urgent transplant alone) is less ideal than LVAD bridge in this unstable profile.\",\n    \"logical_false_reason\": \"T\",\n    \"logical_validity\": true,\n    \"medical_accuracy_score\":", "judge_output_valid": false, "judge_parse_error": "json decode error: Expecting value: line 5 column 30 (char 925)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-003", "question": "A previously healthy 4-year-old boy presents with 10 days of fever to 39.5°C, conjunctival injection without exudate, cracked lips, polymorphous trunk rash, edema and erythema of hands and feet, and cervical lymphadenopathy. Symptoms partially improved after ibuprofen but recur when stopped. Day-10 echocardiogram: diffuse coronary artery ectasia with z-scores 2.3-2.7, mild LV dysfunction (EF 50%), and small pericardial effusion. Labs: WBC 14,000/µL, platelets 520,000/µL, CRP 10 mg/dL, ESR 80 mm/hr, ALT mildly elevated, sterile pyuria. COVID serology and respiratory viral panel are negative. He has not yet received IVIG. What is the most appropriate initial treatment strategy now?", "options": ["Single dose IVIG 2 g/kg plus high-dose aspirin only", "IVIG 2 g/kg, high-dose aspirin, and a single dose of IV methylprednisolone 30 mg/kg", "IVIG 2 g/kg, low-dose aspirin, and infliximab 5 mg/kg", "IVIG 2 g/kg, high-dose aspirin, and anakinra 2 mg/kg/day", "High-dose aspirin alone because presentation is after day 10 of illness"], "answer": "B", "answer_index": 1, "explanation": "He has classic Kawasaki disease with coronary changes and delayed presentation, which confers high risk of IVIG resistance and coronary progression. Current risk-adapted approaches favor adjunctive corticosteroids with IVIG in high-risk patients (coronary involvement and very elevated inflammatory markers), even after day 10. Aspirin monotherapy is inadequate; biologics are reserved for IVIG-resistant disease.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: classic Kawasaki disease (KD) criteria met, day 10 of illness, coronary artery ectasia, elevated inflammatory markers, and no prior IVIG. The vignette describes a high-risk patient (coronary involvement, high inflammatory markers, presentation after day 10), making adjunctive initial therapy with corticosteroids plus IVIG and aspirin a guideline-supported, risk-adapted strategy. No logical issues; the stem provides sufficient detail to discriminate. Options A and E are inadequate monotherapies for high-risk KD. Options C and D involve biologics (infliximab, anakinra) not recommended as first-line initial therapy per major guidelines, which reserve them for IVIG-resistant disease. Medical accuracy is sound, aligning with AHA guidelines. Minimal fix: None required; item is clear and accurate.\",\n  \"logical_false_reason\": \"T\",\n  \"logical_validity\": true,\n  \"medical_accuracy_score\":  \t\n  \"5\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: classic Kawasaki disease (KD) criteria met, day 10 of illness, coronary artery ectasia, elevated inflammatory markers, and no prior IVIG. The vignette describes a high-risk patient (coronary involvement, high inflammatory markers, presentation after day 10), making adjunctive initial therapy with corticosteroids plus IVIG and aspirin a guideline-supported, risk-adapted strategy. No logical issues; the stem provides sufficient detail to discriminate. Options A and E are inadequate monotherapies for high-risk KD. Options C and D involve biologics (infliximab, anakinra) not recommended as first-line initial therapy per major guidelines, which reserve them for IVIG-resistant disease. Medical accuracy is sound, aligning with AHA guidelines. Minimal fix: None required; item is clear and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-004", "question": "A 32-year-old woman with mixed connective tissue disease (U1-RNP positive) on mycophenolate mofetil and low-dose prednisone presents with 3 months of progressive exertional dyspnea and near-syncope. Exam: loud P2, right ventricular heave, no crackles, no edema. HR 94, BP 108/68 mmHg, O2 sat 95% on room air. CT chest: no interstitial lung disease, no PE. TTE: normal LV, moderately dilated RV with reduced function, estimated PASP 75 mmHg, no shunt. Right heart cath: mPAP 46 mmHg, PAOP 9 mmHg, CI 2.0 L/min/m², PVR 9 Wood units. Autoantibodies: strong anti-U1-RNP, negative anti-Scl-70. She desires pregnancy within 1-2 years. What is the most appropriate initial advanced therapy strategy for her pulmonary hypertension?", "options": ["Start amlodipine after acute vasoreactivity testing, then titrate based on BP", "Initiate dual oral therapy with ambrisentan and tadalafil", "Initiate triple therapy including IV epoprostenol plus an endothelin receptor antagonist and a PDE-5 inhibitor", "Start inhaled treprostinil monotherapy and observe functional response", "Use riociguat monotherapy given connective tissue disease-associated PAH"], "answer": "C", "answer_index": 2, "explanation": "She has high-risk WHO group 1 CTD-associated PAH (RV dysfunction, mPAP 46, CI 2.0, PVR 9) and plans pregnancy (a major risk), warranting aggressive up-front therapy. Modern guidelines recommend initial triple therapy with parenteral prostacyclin in high-risk PAH patients. CCBs are only for acute vasoreactivity responders; dual or single oral agents are insufficient for this profile.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: K (Miskeyed). Verdict on keyed answer: Miskeyed. Key stem clues: WHO group 1 CTD-PAH, high-risk features (RV dysfunction, CI 2.0), and pregnancy plans. The most appropriate initial advanced therapy for high-risk PAH is aggressive upfront combination therapy, but the keyed answer (C) mandates IV epoprostenol as part of initial triple therapy. While parenteral prostacyclin is a high-risk option, current guidelines (e.g., ESC/ERS 2022) recommend initial dual oral combination (ERA + PDE5i) for most high-risk patients, with IV prostacyclin considered if inadequate response or highest risk. Option B (ambrisentan + tadalafil) is a guideline-supported, evidence-based initial strategy for this high-risk profile and is more appropriate than immediately starting IV therapy. The key incorrectly prioritizes an overly aggressive, less conventional initial step. Minimal fix: Change key to B, or modify option C to 'Initiate dual oral therapy and consider early addition of parenteral prostacyclin if inadequate response.'\",\n    \"logical_false_reason\": \"K\",\n    \"logical_validity\": false,\n    \"medical_accuracy_score\":  \"3\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict on keyed answer: Miskeyed. Key stem clues: WHO group 1 CTD-PAH, high-risk features (RV dysfunction, CI 2.0), and pregnancy plans. The most appropriate initial advanced therapy for high-risk PAH is aggressive upfront combination therapy, but the keyed answer (C) mandates IV epoprostenol as part of initial triple therapy. While parenteral prostacyclin is a high-risk option, current guidelines (e.g., ESC/ERS 2022) recommend initial dual oral combination (ERA + PDE5i) for most high-risk patients, with IV prostacyclin considered if inadequate response or highest risk. Option B (ambrisentan + tadalafil) is a guideline-supported, evidence-based initial strategy for this high-risk profile and is more appropriate than immediately starting IV therapy. The key incorrectly prioritizes an overly aggressive, less conventional initial step. Minimal fix: Change key to B, or modify option C to 'Initiate dual oral therapy and consider early addition of parenteral prostacyclin if inadequate response.'", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-005", "question": "A 24-year-old primigravida at 11 weeks presents with severe nausea, non-bloody emesis 10-15 times daily, 4-kg weight loss, orthostatic tachycardia, and inability to keep down oral medications despite pyridoxine/doxylamine and rectal promethazine. She has ketonuria, Na 131 mEq/L, K 2.9 mEq/L, bicarbonate 19 mEq/L, ALT 78 U/L, AST 65 U/L, normal lipase and thyroid function. Ultrasound: single viable intrauterine pregnancy. She requests to avoid hospitalization if possible and is anxious about teratogenic risk. What is the most appropriate next-step pharmacologic management in addition to IV fluids and electrolyte repletion?", "options": ["Start oral ondansetron and allow discharge with close outpatient follow-up", "Begin continuous subcutaneous metoclopramide infusion as an outpatient", "Administer IV ondansetron and admit for parenteral nutrition via PICC line", "Start transdermal scopolamine and oral mirtazapine", "Administer IV chlorpromazine now and transition to scheduled IV ondansetron or metoclopramide in the hospital"], "answer": "E", "answer_index": 4, "explanation": "She has hyperemesis gravidarum with significant volume depletion and electrolyte derangements, requiring inpatient care and parenteral antiemetics. Phenothiazines (e.g., IV chlorpromazine) followed by scheduled IV ondansetron or metoclopramide are evidence-based for refractory hyperemesis. Outpatient oral or SC regimens are inappropriate given inability to tolerate PO; TPN is reserved for failure of intensive antiemetic therapy.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: severe hyperemesis gravidarum with inability to tolerate oral intake, significant dehydration/electrolyte abnormalities, and patient's request to avoid hospitalization. The vignette clearly indicates inpatient management is required, making outpatient options (A, B, D) incorrect. The keyed answer (E) recommends IV chlorpromazine, a phenothiazine, but chlorpromazine is not a first-line antiemetic in pregnancy due to significant sedation and extrapyramidal side effects; ondansetron or metoclopramide are preferred. Option C is the most appropriate: IV ondansetron and admission for IV hydration/nutrition (though PICC for TPN is premature). The main logical issue is miskeying; the medically safest and most guideline-consistent choice is not E. Minimal fix: Change the key to C and adjust the rationale to recommend IV ondansetron as first-line, with admission for IV fluids and antiemetics, reserving TPN only if refractory.\",\n  \"logical_false_reason\": \"K\",\n  \"logical_validity\": false,\n  \"medical_accuracy_score\":  \"2\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: severe hyperemesis gravidarum with inability to tolerate oral intake, significant dehydration/electrolyte abnormalities, and patient's request to avoid hospitalization. The vignette clearly indicates inpatient management is required, making outpatient options (A, B, D) incorrect. The keyed answer (E) recommends IV chlorpromazine, a phenothiazine, but chlorpromazine is not a first-line antiemetic in pregnancy due to significant sedation and extrapyramidal side effects; ondansetron or metoclopramide are preferred. Option C is the most appropriate: IV ondansetron and admission for IV hydration/nutrition (though PICC for TPN is premature). The main logical issue is miskeying; the medically safest and most guideline-consistent choice is not E. Minimal fix: Change the key to C and adjust the rationale to recommend IV ondansetron as first-line, with admission for IV fluids and antiemetics, reserving TPN only if refractory.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-006", "question": "A 17-year-old previously healthy boy is admitted to the ICU with septic shock due to meningococcemia, requiring norepinephrine and mechanical ventilation. On day 4, BP stabilizes and pressors are stopped. Over the next 24 hours, he develops rapidly worsening hypoxemia with PaO2/FiO2 ratio 90, diffuse bilateral infiltrates, and new hemoptysis. Hb drops from 11 to 8 g/dL without obvious bleeding. Platelets are 220,000/µL, PT/INR normal, PTT normal, fibrinogen 400 mg/dL. Urinalysis: 3+ blood, 2+ protein, many dysmorphic RBCs. Creatinine rises from 0.8 to 2.1 mg/dL. ANA negative, ANCA panel negative, complements normal. Bronchoscopy shows diffuse alveolar hemorrhage; cultures pending. What is the most appropriate next step in management?", "options": ["High-dose IV methylprednisolone and IV cyclophosphamide for presumed ANCA-negative pulmonary-renal vasculitis", "Plasmapheresis plus pulse steroids for suspected anti-GBM disease despite negative serology", "Supportive care only, assuming septic coagulopathy-related lung injury", "Kidney biopsy as soon as feasible to guide immunosuppression decisions", "Start rituximab and prednisone for suspected immune-complex GN related to sepsis"], "answer": "D", "answer_index": 3, "explanation": "He has a pulmonary-renal syndrome with DAH and GN but negative ANCA/anti-GBM serologies and preserved platelets/coagulation, making pure septic DIC unlikely. In this critically ill patient, tissue diagnosis is essential before committing to aggressive immunosuppression, especially with negative serologies. Early kidney biopsy best clarifies the etiology; empiric cytotoxic therapy or plasmapheresis without diagnosis carries high risk and may be inappropriate if the lesion is infection-related.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: U (Underspecified). Verdict: Not uniquely determinable. Key stem clues: septic shock, then pulmonary-renal syndrome (DAH, hematuria, rising creatinine) with negative serologies (ANA, ANCA, complements) and normal coagulation. The item asks for the 'most appropriate next step' but lacks a critical detail: the patient's hemodynamic stability and bleeding risk for an invasive biopsy. In a critically ill ICU patient with recent shock and new hemoptysis, proceeding directly to kidney biopsy (keyed answer D) is not clearly safer or more urgent than other temporizing steps (e.g., supportive care C or empiric steroids A/B). The rationale emphasizes tissue diagnosis, but the stem underspecifies the patient's fitness for the procedure. Main medical accuracy issue: while biopsy is definitive, immediate empiric immunosuppression or plasmapheresis in a recent septic patient is high-risk, making supportive care a plausible alternative. Minimal fix: Add 'He is now hemodynamically stable, off pressors, and has no active bleeding' to make biopsy the safer, logical next step.\",\n  \"logical_false_reason\": \"U\",\n  \"logical_validity\": false,\n  \"medical_accuracy_score\":  \t\n  \"4\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (Underspecified). Verdict: Not uniquely determinable. Key stem clues: septic shock, then pulmonary-renal syndrome (DAH, hematuria, rising creatinine) with negative serologies (ANA, ANCA, complements) and normal coagulation. The item asks for the 'most appropriate next step' but lacks a critical detail: the patient's hemodynamic stability and bleeding risk for an invasive biopsy. In a critically ill ICU patient with recent shock and new hemoptysis, proceeding directly to kidney biopsy (keyed answer D) is not clearly safer or more urgent than other temporizing steps (e.g., supportive care C or empiric steroids A/B). The rationale emphasizes tissue diagnosis, but the stem underspecifies the patient's fitness for the procedure. Main medical accuracy issue: while biopsy is definitive, immediate empiric immunosuppression or plasmapheresis in a recent septic patient is high-risk, making supportive care a plausible alternative. Minimal fix: Add 'He is now hemodynamically stable, off pressors, and has no active bleeding' to make biopsy the safer, logical next step.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-007", "question": "A 6-week-old full-term girl presents with poor feeding, tachypnea, and sweating with feeds. Weight is at the 3rd percentile (previously 40th). Vitals: HR 180, RR 60, BP 70/40 mmHg in all extremities, O2 sat 96% RA. Exam: hepatomegaly, gallop rhythm, 2/6 holosystolic murmur at apex radiating to axilla, no differential pulses. CXR: cardiomegaly, pulmonary overcirculation. Echo: dilated LV with EF 20%, moderate MR, normal coronaries, no coarctation or structural shunt, normal RV function. ECG: sinus tachycardia. Blood and viral studies pending. After starting IV milrinone and diuretics, she stabilizes. What is the MOST appropriate next step in definitive management planning?", "options": ["Discontinue inotropes as soon as EF improves above 35% and transition to oral heart failure therapy only", "Urgently list for heart transplant as status 1A given high mortality of infantile dilated cardiomyopathy", "Begin high-dose IVIG for presumed viral myocarditis and defer consideration of mechanical support", "Evaluate for durable LVAD candidacy as bridge to transplant or recovery", "Schedule elective mitral valve repair to reduce regurgitation and improve LV function"], "answer": "D", "answer_index": 3, "explanation": "She has severe idiopathic/viral dilated cardiomyopathy with EF 20% and inotrope dependence, placing her at high risk of deterioration. Early evaluation for durable LVAD as bridge to transplant or recovery is recommended in infants with advanced heart failure who respond incompletely to medical therapy. Immediate transplant listing without MCS may be risky given wait times; valve surgery will not address primary LV dysfunction; IVIG alone is insufficient as definitive strategy.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: 6-week-old with severe dilated cardiomyopathy (EF 20%), inotrope-dependent, stabilized on milrinone. The most appropriate next step in definitive management planning for an infant with acute, severe, potentially reversible myocarditis (pending studies) who has stabilized on inotropes is urgent transplant listing (Status 1A), as per pediatric heart failure guidelines, given the high waitlist mortality. While LVAD evaluation (D) is a consideration, it is not the most appropriate immediate next step for planning definitive management in a stabilized infant where transplant is the definitive therapy for irreversible disease. Option B is the guideline-supported best answer. The keyed answer (D) is a plausible but secondary consideration, making the item miskeyed. Medical accuracy is sound. Minimal fix: Change the key to B.\",\n  \"logical_false_reason\": \"K\",\n  \"logical_validity\": false,\n  \"medical_accuracy_score\":  \t\n  \"4\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: 6-week-old with severe dilated cardiomyopathy (EF 20%), inotrope-dependent, stabilized on milrinone. The most appropriate next step in definitive management planning for an infant with acute, severe, potentially reversible myocarditis (pending studies) who has stabilized on inotropes is urgent transplant listing (Status 1A), as per pediatric heart failure guidelines, given the high waitlist mortality. While LVAD evaluation (D) is a consideration, it is not the most appropriate immediate next step for planning definitive management in a stabilized infant where transplant is the definitive therapy for irreversible disease. Option B is the guideline-supported best answer. The keyed answer (D) is a plausible but secondary consideration, making the item miskeyed. Medical accuracy is sound. Minimal fix: Change the key to B.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-008", "question": "A 29-year-old woman at 36+1 weeks with known SLE (class IV lupus nephritis in remission on azathioprine and hydroxychloroquine) presents with 3 days of severe frontal headache, visual blurring, and increasing lower extremity edema. BP 164/102 mmHg (baseline 110/70), HR 92. Labs: platelets 185,000/µL, AST 40 U/L, ALT 35 U/L, creatinine 1.3 mg/dL (baseline 1.1), urine protein/creatinine ratio 2.2 (baseline 1.8), C3 and C4 low, anti-dsDNA titer increased from 1:80 to 1:320, urinalysis with active sediment (RBC casts). Fetus is cephalic, reassuring NST. What is the most appropriate management strategy?", "options": ["Diagnose superimposed preeclampsia with severe features and proceed to immediate delivery", "Increase azathioprine dose and schedule induction at 39 weeks if no further worsening", "Administer IV methylprednisolone for suspected lupus nephritis flare and continue pregnancy with close monitoring", "Start magnesium sulfate and attempt blood pressure control; delay delivery until 37 weeks", "Add IV cyclophosphamide for nephritis flare and plan delivery after disease control"], "answer": "C", "answer_index": 2, "explanation": "She has overlapping features but labs favor SLE flare: rising dsDNA, low complement, active urinary sediment with only mild new proteinuria and preserved platelets/LFTs. At 36 weeks, severe preeclampsia would typically show worsening proteinuria and other end-organ features. Pulse steroids for lupus nephritis flare while continuing pregnancy with close monitoring is appropriate; immediate delivery is not mandatory unless maternal or fetal status deteriorates.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: V. Verdict: Correct best. Key stem clues: SLE with known class IV nephritis, new severe headache/blurring/edema, hypertension, but labs show active SLE flare (rising anti-dsDNA, low complement, RBC casts) with only mild worsening of proteinuria and creatinine, and normal platelets/LFTs. This pattern favors lupus nephritis flare over new-onset severe preeclampsia. Logical issue: None; the item clearly distinguishes flare from preeclampsia based on serology and sediment. Medical accuracy: Accurate; pulse steroids for active lupus nephritis in pregnancy with stable maternal/fetal status is standard. Minimal fix: None required; the item is well-constructed and discriminates based on classic flare markers versus preeclampsia criteria.\",\n    \"logical_false_reason\": \"T\",\n    \"logical_validity\": true,\n    \"medical_accuracy_score\":  \t\n  \"4\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best. Key stem clues: SLE with known class IV nephritis, new severe headache/blurring/edema, hypertension, but labs show active SLE flare (rising anti-dsDNA, low complement, RBC casts) with only mild worsening of proteinuria and creatinine, and normal platelets/LFTs. This pattern favors lupus nephritis flare over new-onset severe preeclampsia. Logical issue: None; the item clearly distinguishes flare from preeclampsia based on serology and sediment. Medical accuracy: Accurate; pulse steroids for active lupus nephritis in pregnancy with stable maternal/fetal status is standard. Minimal fix: None required; the item is well-constructed and discriminates based on classic flare markers versus preeclampsia criteria.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-009", "question": "An intubated 65-year-old woman with severe influenza A pneumonia develops refractory hypoxemia despite lung-protective ventilation (TV 6 mL/kg, PEEP 14 cm H2O, FiO2 0.9) and paralysis. PaO2/FiO2 ratio is 70. She is placed on prone positioning for 16 hours/day with transient improvement but remains PaO2/FiO2 <80. Hemodynamics: MAP 72 mmHg on low-dose norepinephrine, lactate 1.8 mmol/L. No significant comorbidities; BMI 30 kg/m². Family consents to aggressive support. The center has on-site ECMO with experienced team but limited capacity. Which of the following is the most appropriate next step?", "options": ["Increase PEEP to 20 cm H2O and accept permissive hypercapnia before considering ECMO", "Initiate venovenous ECMO now due to refractory severe ARDS despite optimal conventional therapy", "Switch to high-frequency oscillatory ventilation for rescue oxygenation", "Trial inhaled nitric oxide and further proning cycles before deciding on ECMO", "Initiate venoarterial ECMO because of concurrent vasopressor use"], "answer": "B", "answer_index": 1, "explanation": "She has severe ARDS with PaO2/FiO2 <80 despite optimal lung-protective ventilation, high PEEP, paralysis, and proning-meeting criteria for VV-ECMO in an experienced center. Further escalation of ventilator settings or oscillatory ventilation adds risk with limited additional benefit. Low-dose vasopressor does not mandate VA-ECMO; VV-ECMO is appropriate when cardiac function is adequate and shock is not predominant.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: severe ARDS (PaO2/FiO2 70, <80 after proning) refractory to lung-protective ventilation, paralysis, and proning; hemodynamically stable on low-dose vasopressor (MAP 72, lactate 1.8). Main logical issue: None; the stem clearly defines failure of conventional therapy, making VV-ECMO the definitive next step per standard criteria. Main medical accuracy issue: None; the logic aligns with EOLIA trial criteria and current guidelines for ECMO in refractory ARDS. Minimal fix: None required for logical validity; to enhance clarity, the stem could explicitly state 'no signs of cardiogenic shock' to preempt option E.\",\n    \"logical_false_reason\": \"T\",\n    \"logical_validity\": true,\n    \"medical_accuracy_score\":  \t\n  \"5\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: severe ARDS (PaO2/FiO2 70, <80 after proning) refractory to lung-protective ventilation, paralysis, and proning; hemodynamically stable on low-dose vasopressor (MAP 72, lactate 1.8). Main logical issue: None; the stem clearly defines failure of conventional therapy, making VV-ECMO the definitive next step per standard criteria. Main medical accuracy issue: None; the logic aligns with EOLIA trial criteria and current guidelines for ECMO in refractory ARDS. Minimal fix: None required for logical validity; to enhance clarity, the stem could explicitly state 'no signs of cardiogenic shock' to preempt option E.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-010", "question": "A 10-year-old boy with a history of intermittent asthma presents with 3 weeks of fever, weight loss, night sweats, and progressive joint pains. Exam: non-blanching palpable purpura on lower extremities, mononeuritis multiplex with foot drop, and hypertension (130/86 mmHg). No asthma exacerbation. Labs: ESR 90 mm/hr, CRP 12 mg/dL, creatinine 1.1 mg/dL, urinalysis with 1+ protein and few RBCs, hepatitis B surface antigen positive, high HBV DNA titer, negative ANCA. CT angiography: multiple microaneurysms in mesenteric and renal arteries. What is the most appropriate initial treatment strategy?", "options": ["High-dose corticosteroids plus cyclophosphamide without antiviral therapy", "Start entecavir and delay immunosuppression until HBV viral load is suppressed", "High-dose corticosteroids plus plasma exchange and antiviral therapy", "Rituximab with low-dose steroids and entecavir prophylaxis", "Plasma exchange and entecavir only, avoiding immunosuppression"], "answer": "C", "answer_index": 2, "explanation": "He has HBV-associated polyarteritis nodosa with medium-vessel aneurysms and high viral load. Management requires control of both vasculitis and viral replication: short-course high-dose steroids with plasma exchange and concurrent antiviral therapy is recommended. Prolonged cyclophosphamide without antivirals worsens HBV; antivirals alone are insufficient in active PAN; rituximab is less established in HBV-PAN.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict: Correct best. Key stem clues: HBV-positive, systemic symptoms, palpable purpura, mononeuritis multiplex, hypertension, microaneurysms on CT angiography, and high viral load—all consistent with HBV-associated polyarteritis nodosa (PAN). The item correctly requires a strategy addressing both active vasculitis and viral replication. The keyed answer (C: high-dose corticosteroids plus plasma exchange and antiviral therapy) aligns with current guidelines for severe HBV-PAN, which emphasize rapid immunosuppression with steroids and plasma exchange plus immediate antiviral therapy to control viral replication. Alternatives are inferior: A (no antiviral) risks HBV reactivation; B (delayed immunosuppression) allows vasculitis progression; D (rituximab) is not first-line for HBV-PAN; E (no steroids) inadequately treats vasculitis. No contradictions or underspecification; a single best answer is defensible. Minimal fix: none needed; item is clear and accurate.\",\n  \"logical_false_reason\": \"T\",\n  \"logical_validity\": true,\n  \"medical_accuracy_score\":  \t\n  \"5\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best. Key stem clues: HBV-positive, systemic symptoms, palpable purpura, mononeuritis multiplex, hypertension, microaneurysms on CT angiography, and high viral load—all consistent with HBV-associated polyarteritis nodosa (PAN). The item correctly requires a strategy addressing both active vasculitis and viral replication. The keyed answer (C: high-dose corticosteroids plus plasma exchange and antiviral therapy) aligns with current guidelines for severe HBV-PAN, which emphasize rapid immunosuppression with steroids and plasma exchange plus immediate antiviral therapy to control viral replication. Alternatives are inferior: A (no antiviral) risks HBV reactivation; B (delayed immunosuppression) allows vasculitis progression; D (rituximab) is not first-line for HBV-PAN; E (no steroids) inadequately treats vasculitis. No contradictions or underspecification; a single best answer is defensible. Minimal fix: none needed; item is clear and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]